Panacea Biotec launches CABAPAN (Cabazitaxel Injection)

For treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)

Panacea Biotec introduces the indigenously developed high quality oncology product, CABAPAN (Cabazitaxel Injection), for treatment of metastatic Castration Resistant Prostate Cancer (mCRPC).

CABAPAN has been developed by Company's State of the art Global Research and Development Center at Mumbai and manufactured at the Company's production facility complying with global cGMP, at Baddi, Himachal Pradesh.

Powered by Capital Market - Live News